ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2337

Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis

Jonathan Cheah1,2, John A. Carrino3,4, William H. Robinson5,6, Dana Orange7,8, Jackie Szymonifka9, Emily M. Stein1,2 and Susan M. Goodman9,10, 1Medicine, Hospital for Special Surgery, New York, NY, 2Medicine, Weill Cornell Medicine, New York, NY, 3Radiology, Hospital for Special Surgery, New York, NY, 4Radiology, Weill Cornell Medicine, New York, NY, 5VA Palo Alto Health Care System, Palo Alto, CA, 6Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Rockefeller University, New York, NY, 9Hospital for Special Surgery, New York, NY, 10Rheumatology, Weill Cornell Medicine, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: citrullinated vimentin, Fracture risk, fractures, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with RA have high rates of osteoporosis and fractures and RA induces articular and extra-articular bone loss. Seropositivity for any CCP antibody is associated with risk of erosions and osteoporosis. In vitro, human antibodies against citrullinated vimentin bind osteoclast cell surfaces, activate their bone resorptive activity and in an animal model, induce bone loss. In humans, it is not known whether these antibodies are a specific risk factor for osteoporosis. The aim of this study was to assess the prevalence of radiographic vertebral compression fractures (VCF), as a marker of skeletal fragility, in an established RA cohort and whether the presence of antibodies to citrullinated vimentin were associated with this.

Methods:

Data was obtained from a prospective established RA cohort (ACR/EULAR 2010 or ACR 1987 criteria) undergoing elective arthroplasty. VCF were identified on the lateral pre-operative chest radiograph by two independent readers utilizing the Genant semi-quantitative method. Antibodies to citrullinated vimentin epitopes were measured by mean fluorescence intensity utilizing a custom, bead-based, antigen array comprising CCP and RA-associated citrullinated antigens. To identify risk factors predictive of vertebral compression, univariate logistic regression analysis was performed including known potential risk factors for bone loss in RA.

Results:

181 participants had an available chest radiograph. Median age was 65 years [IQR 56, 71] and median disease duration 11 years [IQR 3, 20]. 80% were female, 37% were on current glucocorticoid therapy and 21% had prior exposure. Only 3% self-reported a diagnosis of osteoporosis or use of osteoporosis medications. Despite these numbers, almost half, 76/181 (42%) [58 female] had radiographic VCF (Table 1). Participants with VCF were older [median age 68 years vs. 64 years, p=0.03]. In univariate analysis of potential risk factors, only age was associated with VCF (Table 2). No significant differences were seen in antibody levels, including antibody isotypes to citrullinated vimentin.

Conclusion:

Vertebral compression fractures were prevalent in patients in this established RA cohort. The strongest risk factor for VCF was age. Antibodies to citrullinated vimentin, implicated in early RA models, were not associated with VCF. Our results highlight the profound detrimental skeletal effects of RA. Further studies are needed to investigate the mechanisms of focal versus generalized bone loss, as well as skeletal changes that occur with RA progression.


Disclosure: J. Cheah, None; J. A. Carrino, None; W. H. Robinson, None; D. Orange, None; J. Szymonifka, None; E. M. Stein, None; S. M. Goodman, Roche, Novartis, 4.

To cite this abstract in AMA style:

Cheah J, Carrino JA, Robinson WH, Orange D, Szymonifka J, Stein EM, Goodman SM. Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/vertebral-compression-fractures-and-antibodies-to-citrullinated-vimentin-in-established-rheumatoid-arthritis/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vertebral-compression-fractures-and-antibodies-to-citrullinated-vimentin-in-established-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.